Cardinal Capital Management Purchases 1,371 Shares of Eli Lilly and Company (LLY)

Cardinal Capital Management raised its position in Eli Lilly and Company (NYSE:LLY) by 2.8% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 49,832 shares of the company’s stock after buying an additional 1,371 shares during the quarter. Eli Lilly and comprises about 1.3% of Cardinal Capital Management’s holdings, making the stock its 27th largest position. Cardinal Capital Management’s holdings in Eli Lilly and were worth $4,262,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Stratos Wealth Partners LTD. boosted its position in shares of Eli Lilly and by 6.1% during the 1st quarter. Stratos Wealth Partners LTD. now owns 10,225 shares of the company’s stock worth $860,000 after purchasing an additional 585 shares in the last quarter. FMR LLC boosted its position in shares of Eli Lilly and by 50.6% during the 1st quarter. FMR LLC now owns 1,965,660 shares of the company’s stock worth $165,331,000 after purchasing an additional 660,441 shares in the last quarter. Advantus Capital Management Inc boosted its position in shares of Eli Lilly and by 0.4% during the 1st quarter. Advantus Capital Management Inc now owns 97,698 shares of the company’s stock worth $8,217,000 after purchasing an additional 425 shares in the last quarter. Modera Wealth Management LLC purchased a new stake in shares of Eli Lilly and during the 1st quarter worth $238,000. Finally, Partnervest Advisory Services LLC boosted its position in shares of Eli Lilly and by 12.4% during the 1st quarter. Partnervest Advisory Services LLC now owns 5,820 shares of the company’s stock worth $489,000 after purchasing an additional 643 shares in the last quarter. 76.43% of the stock is currently owned by institutional investors.

Several brokerages have commented on LLY. BMO Capital Markets restated a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a research report on Thursday, September 28th. Cowen reiterated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Jefferies Group reiterated a “buy” rating and issued a $89.00 price objective (down from $94.00) on shares of Eli Lilly and in a research report on Thursday, August 24th. Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Finally, BidaskClub lowered shares of Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $90.25.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 628,588 shares of company stock valued at $53,399,536. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Company (LLY) traded up $0.48 during midday trading on Wednesday, hitting $86.06. 3,876,700 shares of the stock were exchanged, compared to its average volume of 3,672,667. Eli Lilly and Company has a one year low of $66.39 and a one year high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. The firm has a market cap of $94,231.72, a P/E ratio of 20.92, a P/E/G ratio of 1.88 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the prior year, the company posted $0.88 EPS. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. analysts expect that Eli Lilly and Company will post 4.21 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.42%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio is currently 98.58%.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/06/cardinal-capital-management-purchases-1371-shares-of-eli-lilly-and-company-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit